Vericel (VCEL) to Announce Quarterly Earnings on Thursday

Vericel (NASDAQ:VCEL) is anticipated to issue its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $72.6880 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:30 AM ET.

Vericel (NASDAQ:VCEL) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. Vericel had a net margin of 7.35% and a return on equity of 6.41%. The company had revenue of $68.43 million for the quarter, compared to analyst estimates of $63.68 million. During the same period last year, the firm earned ($0.23) earnings per share. The firm’s revenue was up 30.1% on a year-over-year basis. On average, analysts expect Vericel to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Vericel Stock Performance

Vericel stock opened at $44.56 on Thursday. Vericel has a fifty-two week low of $28.95 and a fifty-two week high of $48.75. The stock has a market cap of $2.28 billion, a PE ratio of 106.10 and a beta of 1.07. The firm’s 50-day simple moving average is $40.32 and its 200 day simple moving average is $37.01.

Insider Activity at Vericel

In other Vericel news, CFO Joseph Anthony Mara, Jr. sold 5,000 shares of the business’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $44.75, for a total value of $223,750.00. Following the transaction, the chief financial officer directly owned 16,009 shares in the company, valued at $716,402.75. The trade was a 23.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sean C. Flynn sold 15,000 shares of the stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $45.64, for a total transaction of $684,600.00. Following the transaction, the insider directly owned 1,647 shares of the company’s stock, valued at $75,169.08. This represents a 90.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 47,732 shares of company stock worth $2,084,167. 7.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Vericel

A number of hedge funds have recently modified their holdings of VCEL. State Street Corp lifted its stake in Vericel by 12.7% in the fourth quarter. State Street Corp now owns 3,163,922 shares of the biotechnology company’s stock valued at $113,933,000 after purchasing an additional 356,680 shares during the last quarter. Geode Capital Management LLC increased its position in Vericel by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 1,222,263 shares of the biotechnology company’s stock worth $44,021,000 after buying an additional 7,197 shares during the last quarter. Loomis Sayles & Co. L P increased its position in Vericel by 5.1% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,056,705 shares of the biotechnology company’s stock worth $38,052,000 after buying an additional 50,967 shares during the last quarter. Champlain Investment Partners LLC lifted its position in shares of Vericel by 4.2% during the 4th quarter. Champlain Investment Partners LLC now owns 1,028,847 shares of the biotechnology company’s stock valued at $37,049,000 after buying an additional 41,248 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Vericel by 2.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 815,620 shares of the biotechnology company’s stock worth $29,372,000 after acquiring an additional 17,765 shares during the period.

Wall Street Analyst Weigh In

VCEL has been the subject of several analyst reports. Wall Street Zen upgraded shares of Vericel from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Weiss Ratings upgraded Vericel from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 16th. HC Wainwright reaffirmed a “buy” rating and set a $64.00 price target on shares of Vericel in a research report on Friday, May 8th. Finally, Truist Financial increased their price target on Vericel from $42.00 to $54.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $55.50.

About Vericel

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.